Stromal p16 expression was absent or weak in benign lesions, whereas the majority of malignant lesions exhibited diffuse and moderate-to-strong p16 immunoreactivity, suggesting that stromal p16 expression can be used as an adjunctive biomarker reflecting the development of ovarian carcinoma. The gene discussed is CDKN2A; the disease is ovarian carcinoma.